693 related articles for article (PubMed ID: 22190392)
1. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
[TBL] [Abstract][Full Text] [Related]
2. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
[TBL] [Abstract][Full Text] [Related]
3. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
[TBL] [Abstract][Full Text] [Related]
4. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice.
Cao W; Kim JH; Reber AJ; Hoelscher M; Belser JA; Lu X; Katz JM; Gangappa S; Plante M; Burt DS; Sambhara S
Vaccine; 2017 Jun; 35(25):3318-3325. PubMed ID: 28499553
[TBL] [Abstract][Full Text] [Related]
5. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
[TBL] [Abstract][Full Text] [Related]
6. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
8. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
[TBL] [Abstract][Full Text] [Related]
10. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
11. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
Front Immunol; 2019; 10():646. PubMed ID: 30984200
[TBL] [Abstract][Full Text] [Related]
12. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
13. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
14. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
[TBL] [Abstract][Full Text] [Related]
16. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge.
Plante M; Jones T; Allard F; Torossian K; Gauthier J; St-Félix N; White GL; Lowell GH; Burt DS
Vaccine; 2001 Oct; 20(1-2):218-25. PubMed ID: 11567767
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
Madhun AS; Haaheim LR; Nilsen MV; Cox RJ
Vaccine; 2009 Dec; 27(52):7367-76. PubMed ID: 19781678
[TBL] [Abstract][Full Text] [Related]
19. Development of adjuvant nanocarrier systems for seasonal influenza A (H3N2) vaccine based on Astragaloside VII and gum tragacanth (APS).
Yakuboğulları N; Genç R; Çöven F; Nalbantsoy A; Bedir E
Vaccine; 2019 Jun; 37(28):3638-3645. PubMed ID: 31155418
[TBL] [Abstract][Full Text] [Related]
20. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]